Teva names Michael Hayden CSO
This article was originally published in Scrip
Dr Michael Hayden has joined Teva as president of global research and development and chief scientific officer, based in Israel. He is currently Killam Professor of Medical Genetics at the University of British Columbia, and Canada Research Chair in Human Genetics and Molecular Medicine. He is also the founder and director/senior scientist of the Centre for Molecular Medicine and Therapeutics at the University of British Columbia.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.